54 results about "Myelin sheath" patented technology

This disclosure relates to the field of therapeutic tyrosine kinase inhibitors, in particular, Bruton tyrosine kinase (“BTK”) inhibitors, for treatment of subjects with myelin oligodendrocyte glycoprotein antibody disease (MOGAD).

To provide a method for generating oligocortical spheroids (OCS) from pluripotent stem cells (PSC).SOLUTION: A method comprises the steps for: a) generating a neurocortical spheroid (NCS) through neurocortical patterning of pluripotent stem cells; b) subjecting the neurocortical spheroid to timed exposure to defined oligodendrocyte lineage growth factors and / or hormones, to promote proliferation, survival and / or expansion of native oligodendrocyte progenitor cell (OPC) populations within the neurocortical spheroid, thereby generating the oligocortical spheroid, wherein the oligocortical spheroid contains oligodendrocyte progenitor cells capable of differentiating into myelinating oligodendrocytes (ODCs) that are capable of myelinating axons.SELECTED DRAWING: Figure 1-1

To provide a method of treating an inflammatory neurological disease or condition that can result in destruction or degeneration of axons or myelin.SOLUTION: Provided is a combination comprising a) a compound of formula (I) or a pharmaceutically or veterinarily acceptable salt thereof; and b) one or more drugs selected from the group consisting of I) a compound of a particular formula or a pharmaceutically or veterinarily acceptable salt thereof; ii) a sphingosine-1-phosphate receptor inhibitor (S1PR modulator); and iii) a signal transducer and activator of transcription 3 (STAT3) inhibitor.SELECTED DRAWING: None

A method of generating oligodendroglial progenitor cells and pre-myelinating oligodendrocytes is disclosed. Uses of the cell populations are further described.

The disclosure provides methods for (i) treating multiple sclerosis in patient, (ii) treating a patient having symptoms of multiple sclerosis, (iii) preventing the onset of multiple sclerosis symptoms in patient having multiple sclerosis or predisposed to multiple sclerosis; (iv) promoting or enhancing immunomodulation and remyelination and / or myelin repair in a subject in need thereof; (v) a neuroinflammatory disorder; (vi) Amyotrophic Lateral Sclerosis; or (vii) a demyelinating disease or disorder or a hypomyelinating condition, each method comprising administering a therapeutically effective amount of a bryostatin compound to the patient.

The invention relates to an antibody which binds to myelin oligodendrocyte glycoprotein (MOG), an antibody fragment thereof, a hybridoma which produces the antibody or the antibody fragment, a nucleic acid containing a nucleotide sequence which encodes the antibody or the antibody fragment, a transformant cell containing a vector containing the nucleic acid, a method for producing the antibody or the antibody fragment, a composition containing the antibody or the antibody fragment and a method for detecting or measuring an antigen that is present in the brain, a method for diagnosing or treating a brain disease, a method for improving the property of an antibody of accumulating in the brain and a method for increasing the amount of an antibody in the brain which use the antibody or the antibody fragment.

The invention discloses a magnetic control electric three-layer composite nerve scaffold for nerve regeneration microenvironment stage adaptation and a preparation method thereof. The outer layer of the stent is a PLLA-IAA membrane responding to inflammation microenvironment stimulation, the middle of the stent is an SPIONs-doped piezoelectric layer, and the inner layer of the stent is an Nrg-1-loaded neurotrophic factor sustained release layer. In the initial stage of stent implantation, reactive oxygen species (ROS) stimulates a responsive chain segment to break, and IAA is quickly released to inhibit an inflammatory microenvironment; then, an alternating magnetic field is applied to cause vibration of the SPIONs, formation of an electric signal in the piezoelectric layer is triggered, and a favorable electrophysiological microenvironment is provided for promoting neuronal differentiation and axon regeneration; under the action of environmental degradation, the spinning membrane structure disintegrates slowly and continuously releases the neurotrophic factor Nrg-1 so as to promote myelin sheath formation. The stent innovatively integrates the requirements of three stages of a nerve regeneration microenvironment, and realizes accurate, dynamic and multi-dimensional regulation and control of high-efficiency regeneration.

The application belongs to the technical field of biological drugs, and particularly relates to a preparation method of genetically modified human bone marrow mesenchymal stem cells and application thereof in treating nervous system diseases, in particular, multiple sclerosis. The human bone marrow mesenchymal stem cells are double-modified by brain-derived neurotrophic factor (BDNF) and anti-S1PR5 nanobody, so that the activity of the human bone marrow mesenchymal stem cells is improved, the survival of neurons or oligodendrocytes is promoted, cell apoptosis is inhibited, and myelin regeneration is promoted, and the human bone marrow mesenchymal stem cells can be applied to nervous system diseases, in particular, multiple sclerosis.

The invention provides a composite active dressing for neural restoration and a preparation method and application thereof, and relates to the technical field of medical materials. The composite active dressing comprises a transdermal inner layer and a small extracellular vesicle slow-release outer layer, the transdermal inner layer is of a membrane-shaped structure and comprises a composite active component and a hydrogel matrix material, and the composite active component is selected from one or more of an anti-inflammatory component, a microcirculation improving component, an antioxidant component and a neurotrophic component; the small extracellular vesicle sustained-release outer layer is of a three-dimensional network structure and comprises small extracellular vesicles and a hydrogel matrix material. According to the invention, stable loading and layered deep delivery and release of the small extracellular vesicles are realized, the inflammatory response and microcirculation state of an injured part are improved, proliferation migration and remyelination of Schwann cells can be promoted, and axon regeneration and effective repair of nerve injury can also be promoted.

The utility model discloses a device convenient for exploring laboratory mouse habits, which comprises a laboratory mouse habit exploring device, a plurality of independent control cabins are arranged in an upper box body of the laboratory mouse habit exploring device at equal angles, and ventilation openings are arranged above the outer arc-shaped side walls of the independent control cabins in a matched mode. A plurality of independent control cabins are arranged on the experimental mouse habit exploration device, humidity controllers and controllable illuminating lamps are arranged in top covers of the independent control cabins at equal angles, temperature control tubes are arranged at the bottoms of the independent control cabins, the independent control cabins are communicated with the central multi-through groove, the experimental mouse habit exploration device is provided with the independent control cabins, and each independent control cabin can achieve simulation of different environments. In this way, the adaptive capacity of the mouse to the environment can be better explored, different external environments can generate different environmental stimuli to the mouse, the external environments can well induce the animal to generate immune response aiming at the myelin sheath component of the central nervous system (CNS), research data can be well compared, and the research result is more accurate. And the data accuracy is higher.

The application discloses application of a Histatin-1 polypeptide in preparation of a preparation for promoting sciatic nerve regeneration or repair, and an amino acid sequence of the Histatin-1 polypeptide is shown as SEQ ID NO. 1. The Histatin-1 polypeptide can promote expression of a nerve differentiation index, promote recovery of a functional index after sciatic nerve injury, and promote recovery of a histological index after sciatic nerve injury, for example, recovery of myelin structure and morphology. In addition, in combination with gelatin methacrylate (Gel-MA) as a biological scaffold, slow release of the Histatin-1 polypeptide can be realized, continuous repair support can be provided for a nerve injury site, myelin repair effect is further optimized, a more efficient and more durable solution is provided for treatment of sciatic nerve injury, and the application has a wide application prospect in the field of treatment of myelinated nerve injury.

The present invention relates to a contrast agent composition capable of specifically staining nerve tissue, in which the composition has affinity for myelin and can specifically stain nerve tissue rather than other tissues, has a wavelength in the near-infrared (NIR) region of 700 nm, and can stably emit fluorescence in vivo, and thus can be effectively used for real-time fluorescence imaging to differentiate from other tissues.

The invention provides an application of a nitrogen-containing heterocyclic ring compound in preparation of a medicine for treating peripheral neuropathy. The nitrogen-containing heterocyclic ring compound is SB203580. The peripheral neuropathy refers to diseases or injuries involving a peripheral nervous system, and comprises peripheral nerve trauma, adverse drug reaction and axonal dysfunction caused by one or more pathogenic factors of chemical reagents and diabetes mellitus. Researches show that recovery of a sciatic nerve function index (SFI) after peripheral nerve physical injury (sciatic nerve truncation) of a mouse is remarkably improved, the recovery degree of the signal transduction rate of the injured sciatic nerve is improved, myelin sheath regeneration of the injured sciatic nerve is promoted, and the proportion of abductive myelin sheaths in newly formed myelin sheaths is reduced. The invention provides a new potential medicine for treating the peripheral nerve injury. The structure of the SB203580 is shown in the specification.

Apparatus for the non-invasive in-vivo determination of changes in tissue, e.g. the myelination, of the optic nerve (ON) in a biological subject, said apparatus comprising: a laser source for generating an excitation laser beam; an optical system including a fundus camera operatively associated with the laser source for use in obtaining a fundus image for illuminating the optic nerve (ON) of a subject with the excitation laser beam; a detector (13) operatively associated with the optical system and configured to detect a Raman spectrum from the optic nerve (ON) and / or surrounding cerebral spinal fluid; and a processor provided with a computer program for comparing the detected Raman spectrum to at least one reference spectrum. The reference spectrum may correspond to the myelination of the optic nerve in a normal, healthy subject, for determining the changes in the myelination of the optic nerve of the subject based on the detecting and comparing steps from the Raman spectrum.

The present application relates to a kind of drug composition for preventing and treating recovery stage facial nerve palsy and its application, the composition contains any one or its combination of dehydrating drug, antiviral drug, anti-inflammatory drug, nerve repair drug and / or blood circulation improving drug, traditional Chinese medicine preparation.The drug composition of the present application is combined with radio frequency operation and nerve repair drug and rehabilitation exercise, beneficial to promote trophic nerve, promote myelin and axon repair, with synergistic effect, fast effect, high efficiency, high cure rate, basically no side effect and basically no recurrence rate and the like, significantly improve the treatment prognosis and quality of life of patient.

The application discloses a diagnostic marker detection system of a star-shaped glial cell IL-33 knockout EAE model, relates to the technical field of in vitro diagnosis, and comprises the following steps: constructing direction consistency constraint, four-domain prior weight and anchor point consistency scoring; selecting a minimum panel in four domains of inflammation chemotaxis, T cell subgroups, myelin axons and blood brain barrier, and generating Th17 / Th1 and MMP9 / closure protein ratio and chemotaxis combination; implementing standardized collection, platform alignment and bridge calibration, establishing intra-batch / between-batch quality control and time window limitation; performing learning with monotone constraint and two-stage calibration, and reserving animal-to-human population domain adaptation; and outputting star source index, double-threshold value stratification, longitudinal monitoring and interpretable report, so that cross-platform and cross-batch comparability, direction order preservation, traceability and clinical bridgeability are realized, and robust discrimination and reproducibility are improved.

A system for treating a subject including a signaling device, a controller, and a stimulator. The signaling device is in communication with the input of the controller and is configured to send a signal to the controller. The stimulator is in communication with the output of the controller and is configured to stimulate an auricular branch of a vagus nerve in an ear of a subject in response to the controller receiving the signal from the signaling device.

A method of generating oligodendroglial progenitor cells and pre-myelinating oligodendrocytes is disclosed. Uses of the cell populations are further described.

The application belongs to the technical field of biological medicine, and particularly relates to application of circular RNA as a marker in detection of hand-foot-mouth disease complicated with nerve injury. The application first discovers that hsa_circ_0069335 as a marker is applied in prediction of hand-foot-mouth disease complicated with nerve injury. In an external verification queue, there is no marker in serum samples of patients with nerve injury symptoms, and the area under the ROC curve is 1, which indicates that the marker can be used as a marker of hand-foot-mouth disease complicated with nerve injury, and has excellent specificity and sensitivity. Further, the application discovers that EV71 infection inhibits growth of Schwann cells, myelin formation is damaged, and causes significant damage to the nervous system, which is related to the hsa_circ_0069335 / miR-29b-3p / PMP22 pathway. The discovery may provide a key molecular target for early warning and treatment of severe hand-foot-mouth disease, so as to accelerate the development progress of therapeutic drugs.

The present invention provides antisense oligonucleotide conjugates targeting the PMP22 gene, and methods of using such antisense oligonucleotide conjugates to inhibit expression of PMP22 and to treat subjects having a disease, such as Charcot-Marie-Tooth (CMT) disease, e.g., CMT1A disease.

The invention discloses an extracellular vesicle for treating facial nerve injury and a preparation method thereof. The hNSCs-EVs are separated from an hNSCs conditioned culture medium through an ultracentrifugation method, the particle size of the hNSCs-EVs is 100-150nm, and the hNSCs-EVs express CD9, CD63 and TSG101 markers. Experiments prove that when hNSC-EVs is locally injected to the injured part of facial nerves, functional recovery of the facial nerves can be remarkably promoted, electrophysiological signals can be improved, and axon regeneration, myelin sheath formation and Schwann cell activation can be effectively promoted. The invention provides a brand new treatment strategy which is safe, effective, easy to store and standard for facial nerve injury, and has a wide clinical application prospect.

Methods of inducing rejuvenation in a population of adult glial progenitor cells, and methods of treating a subject having a myelin deficiency are disclosed in this patent application. The method of inducing rejuvenation in a population of adult glial progenitor cells may comprise administering, to the population of adult glial progenitor cells, an effective amount of an agent that suppresses one or more transcription factors selected from the group consisting of (i) zinc finger protein 274 (ZNF274), (ii) Myc-associated factor X (MAX), (iii) E2F transcription factor 6 (E2F6), (iv) zinc finger protein Aiolos (IKZF3), and (v) signal transducer and activator of transcription 3 (STAT3).

The present application belongs to the field of animal models, and more specifically, a method for constructing an autism spectrum disorder mouse model by BAF155 conditional knockout mode is disclosed. By constructing a specific knockout BAF155 mouse, the effect of knockout BAF155 on OL development and myelination is observed. Further proved by the behavior experiment, the deletion of BAF155 in oligodendrocyte precursor cells will lead to the appearance of the core and characteristic ASD-like behavior phenotype of mice mainly with social preference disorder and repetitive stereotyped behavior. Therefore, the present application successfully constructs a new genetic molecular defect ASD animal model, and the advantage lies in that the target is clear, a single genetic molecular defect can be induced to study ASD, and a suitable and matched animal model for ASD caused by mutation of BAF155 is provided, which is helpful for precise diagnosis and subsequent intervention strategy.

The invention provides walnut-derived extracellular membrane vesicles and application thereof in peripheral nerve injury repair, and relates to the technical field of biological medicines. The walnut-derived extracellular membrane vesicles (WEVs) prepared by the invention show typical vesicle form and nano-scale particle size distribution, and can still keep structural integrity after freeze-drying and long-term storage, thereby supporting the feasibility of standardized preparation and preservation of the walnut-derived extracellular membrane vesicles (WEVs). In the functional level, the WEVs can be efficiently internalized by Schwann cells (SCs) through an energy-dependent process, and the process accords with gridding protein mediated endocytosis characteristics; meanwhile, the WEVs show good biocompatibility and biological safety in vitro and in vivo. In addition, the WEVs can promote remyelination of PNI model rats, improve motion and sensory functions of the PNI model rats and relieve muscular atrophy conditions of the PNI model rats, and has an obvious treatment effect on the PNI model rats. The WEVs are expected to be used as a plant-derived nano candidate drug for treating peripheral nerve injury.

The invention discloses application of liver ORM2 as an intervention target in improvement of white matter injury and related diseases. According to the application, the influence of liver targeted intervention ORM2 on white matter injury is evaluated through a CPZ-induced white matter injury model, and a result shows that the ORM2 level in brain tissues can be remarkably reduced by targeted liver specific inhibition ORM2 through AAV (adeno-associated virus), CPZ-induced cognitive and activity disorders are improved, the myelin sheath thickness and integrity are improved, and the application has the advantages of being capable of effectively reducing the expression level of the ORM2 in the brain tissues, reducing the expression level of the ORM2 in the brain tissues and reducing the expression level of the ORM2 in the brain tissues. And the number of Olig2 / CC1 positive oligodendroglia cells is increased. The application provides a new target and a central nervous system external medicine intervention scheme for treating white matter injury related diseases, and has a good clinical application prospect.

The present disclosure provides the use of ATDR and ATDRA in treating white matter diseases, in particular, provides the use of all-trans-13,14-dihydroretinol (ATDR) and / or all-trans-13,14-dihydroretinoic acid (ATDRA) or a pharmaceutically acceptable salt thereof, or a composition comprising all-trans-13,14-dihydroretinol (ATDR) and / or all-trans-13,14-dihydroretinoic acid (ATDRA) or a pharmaceutically acceptable salt thereof, retinol saturase (Retsat) or a variant thereof, a nucleic acid encoding Retsat or a variant thereof, an expression cassette comprising a nucleic acid encoding Retsat or a variant thereof, a vector comprising a nucleic acid encoding Retsat or a variant, a cell expressing Retsat or a variant thereof in the preparation of a medicament for preventing and / or treating white matter diseases in a subject in need thereof, which can promote the differentiation of oligodendrocytes and myelination to treat white matter diseases.

Provided herein are compositions and methods for treating neuroinflammatory diseases and conditions, the neuroinflammatory diseases and conditions include Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), traumatic brain injury (TBI), complex regional pain syndrome (CRPS), optic neuritis (ON), optic neuromyelitis (NMO), chronic traumatic encephalopathy (CTE), ischemic stroke (IS), vascular dementia (VAD), anti-oligodendroglia glycoprotein antibody disease (MOGAD), and the like. Transverse myelitis (TM), autoimmune encephalitis (AE), acute disseminated encephalomyelitis (ADEM), chronic meningitis (CM), central nervous system (CNS) vasculitis, hashimoto encephalitis (HE), neurosarcoidosis (NS), multi-system atrophy (MSA), migraine, chemotherapy-induced pain or dementia-related pain.

The invention provides application of glycopyrronium bromide in preparation of a medicine for treating nervous system diseases, and belongs to the technical field of biological medicines. The research finds that the novel drug glycopyrronium bromide shows a clear and excellent technical effect in the aspect of treating nervous system diseases, on one hand, the glycopyrronium bromide can inhibit the inflammatory response of glial cells by reducing infiltration of central mononuclear macrophages (MDM); on the other hand, differentiation and maturation of oligodendroglia precursor cells (OPCs) into oligodendroglia cells can be effectively promoted, and the effect of promoting myelin sheath regeneration is achieved. Multiple sclerosis is effectively improved through the dual effects of inhibiting glial cell inflammation and promoting myelin regeneration, and the medicine is a candidate medicine with great potential for treating progressive multiple sclerosis (MS).

The invention provides the application of SCD1 in preparing the medicine for treating the nerve myelin sheath injury diseases, the application reveals that SCD1 serves as a brand-new target spot for treating the sciatic nerve myelin sheath injury diseases for the first time, the target spot blank of existing targeted lipid metabolism regulation myelin sheath regeneration medicine is filled, and all-around repairing can be achieved from the molecule, form and function level; on one hand, the SCD1 can up-regulate expression of genes such as PMP22 and MPZ and promote myelin sheath synthesis from the source, and on the other hand, the SCD1 can also increase the myelin sheath thickness, reduce the number of non-marrow nerves and improve the structural integrity and stability of regenerated myelin sheaths; meanwhile, the SCD1 can prolong the dwell time of the rotating rod, accelerate the nerve conduction speed and improve dyskinesia and nerve conduction abnormity after sciatic nerve injury; besides, regulation of endogenous lipid metabolism is taken as a core mechanism, an intervention mode is safe and controllable, an experimental system is mature and repeatable, and an efficient, stable and safe new strategy is provided for clinical treatment of sciatic nerve myelin sheath injury.